Skip to content

Comparison of Brain Perfusion in Rhythm Control and Rate Control of Persistent Atrial Fibrillation

Comparison of Brain Perfusion in Rhythm Control and Rate Control of Persistent Atrial Fibrillation: Prospective Randomized Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02633774
Enrollment
200
Registered
2015-12-17
Start date
2015-11-30
Completion date
2020-11-30
Last updated
2019-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Persistent Atrial Fibrillation

Brief summary

Atrial fibrillation (AF) is associated with impaired cognitive function (CogF) and/or dementia, but it is unclear whether rhythm control of AF improves CogF or brain perfusion. The hypothesis is rhythm control of AF improves CogF by increasing brain perfusion with hemodynamic amelioration compared to AF state. We will randomize the patients with persistent AF to rhythm control group and rate control group, and check baseline and 3rd month cognitive function (K-MOCA score) and brain perfusion CT. K-MOCA score and brain perfusion CT findings will be compared between rhythm control group and rate control group of persistent AF.

Interventions

AAD(antiarrhythmic drug)

DRUGApixaban

anti-coagulation

Sponsors

Yonsei University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
20 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Patients with persistent Atrial fibrillation (20\ 80 years old) * LA diameter \< 55mm * patients possible to anticoagulation and anti arrhythmic drug

Exclusion criteria

* Structural cardiac disease * Contraindication to brain perfusion CT * Catheter ablation history for AF, Cardiac surgery * active internal bleeding * Impossible to anticoagulation or antiarrhythmic drug * valvular AF ((MA\> GII, Mechanical valve, Mitral valve replacement) * LVEF \< 30% * With severe medical disease * Expected survival \< 1 year * Severe alcoholics, drug addiction

Design outcomes

Primary

MeasureTime frame
K-MOCA(Korean version of Montreal Cognitive Assessment)12 months after the enrollment
Brain perfusion CT12 months after the enrollment

Countries

South Korea

Contacts

Primary ContactHui-Nam Park, MD, Ph.D
hnpak@yuhs.ac82-2-2228-8459

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026